Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) received a Nasdaq Hearings Panel decision granting continued listing, conditional on regaining compliance with Listing Rule 5550(a)(2) (Bid Price Rule) by July 31, 2026. The company reports full compliance with all other listing requirements.
Shareholders will vote on a proposed reverse stock split at a special meeting on June 18, 2026, which, if approved, is expected to be implemented at a Board-selected ratio to help meet the bid price requirement.
AI-generated analysis. Not financial advice.
Positive
- Nasdaq Hearings Panel grants conditional continued listing for XAIR
- Deadline to regain bid price compliance extended to July 31, 2026
- Company reports compliance with all other Nasdaq listing requirements
- Reverse stock split proposal provides a concrete pathway to meet bid price rule
Negative
- Current non-compliance with Nasdaq Bid Price Rule 5550(a)(2)
- Continued listing remains contingent on meeting bid price requirement by July 31, 2026
- Potential reverse stock split may change share structure if shareholders approve
News Market Reaction – XAIR
On the day this news was published, XAIR gained 5.70%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $349K to the company's valuation, bringing the market cap to $6.47M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows mixed peer action, with AIMD up 6.72% and CODX down 12.08% while the scanner classifies XAIR’s direction as down, indicating this listing update is stock-specific rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Clinical update | Positive | +0.2% | Updated Phase 1 UNO survival data and gas-delivery patent allowance. |
| Apr 15 | Conference participation | Neutral | -11.6% | Management participation and one-on-one meetings at investor conference. |
| Apr 01 | Commercial agreement | Positive | +3.5% | National GPO deal expanding LungFit PH access to ~2,000 hospitals. |
| Mar 26 | Leadership change | Neutral | +0.2% | CEO transition from Steven Lisi to Robert Goodman with continuity messaging. |
| Mar 17 | Clinical update | Positive | +0.3% | Interim Phase 1 UNO data showing early activity and favorable safety. |
Recent fundamentally positive and clinical updates have generally seen small positive price moves, while non-fundamental events like conference participation have occasionally drawn negative reactions.
Over the last few months, Beyond Air has combined clinical, commercial, and governance milestones with listing-related challenges. Positive Phase 1 UNO data on Mar 17 and updated survival plus a patent allowance on Apr 20 both saw modest gains. A major LungFit PH GPO agreement on Apr 1 also produced a small positive reaction. In contrast, a neutral conference appearance on Apr 15 coincided with a double‑digit decline. Today’s Nasdaq Panel decision directly follows April 8‑K disclosures about bid‑price noncompliance and the reverse-split proxy process.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Jan 30, 2026 covers 524,990 existing shares plus additional warrant shares, mainly enabling resales by existing holders. Beyond Air would receive cash only if pre-funded warrants at $0.0001 or common warrants at $1.147 are exercised before their Jan 16, 2031 expiry. This structure can add tradable float over time but does not itself raise primary capital.
Market Pulse Summary
The stock moved +5.7% in the session following this news. A strong positive reaction aligns with relief around continued Nasdaq listing, as the Panel’s decision removes immediate delisting risk while setting a July 31, 2026 deadline to fix the bid price. Investors have seen prior reliance on reverse splits, and a new split vote on June 18, 2026 presents execution risk. The existing S-3 shelf and warrant overhang could also influence future trading once compliance steps are taken.
Key Terms
nasdaq hearings panel regulatory
listing rule 5550(a)(2) regulatory
reverse stock split financial
AI-generated analysis. Not financial advice.
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC’s (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026. The Company is fully compliant with all other continued listing requirements.
“We appreciate the Panel’s thoughtful review and support of our compliance plan," said Robert Goodman, Chief Executive Officer of Beyond Air. “This decision provides us with the time needed to complete the steps necessary to regain compliance while we remain focused on advancing our commercial execution and progressing our next-generation portable nitric oxide platform.”
As previously disclosed, Beyond Air’s shareholders will vote on a proposal authorizing a reverse stock split at the Company’s special meeting of stockholders on June 18, 2026. If approved, the Company expects to implement the reverse stock split at a ratio deemed appropriate by its Board of Directors to facilitate regaining compliance with the Nasdaq bid price requirement.
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2); the timing, approval, implementation, and effectiveness of any reverse stock split; the Company’s ability to maintain its listing on The Nasdaq Stock Market, the Company’s commercial growth and expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance; advancement and development of the Company’s next-generation portable nitric oxide platform and other product candidates; future financing activities and capital resources. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, and are not guarantees of future performance.
Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements within the required time periods or at all; the outcome of the Company’s special meeting of stockholders and the approval and implementation of any reverse stock split; the effectiveness of any reverse stock split in increasing or maintaining the market price of the Company’s common stock; the Company’s ability to maintain its Nasdaq listing; the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.
CONTACTS:
Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
